98%
921
2 minutes
20
Drug toxicity prediction is essential to drug development, which can help screen compounds with potential toxicity and reduce the cost and risk of animal experiments and clinical trials. However, traditional handcrafted feature-based and molecular-graph-based approaches are insufficient for molecular representation learning. To address the problem, we developed an innovative molecular fingerprint Graph Transformer framework (MolFPG) with a global-aware module for interpretable toxicity prediction. Our approach encodes compounds using multiple molecular fingerprinting techniques and integrates Graph Transformer-based molecular representation for feature learning and toxic prediction. Experimental results show that our proposed approach has high accuracy and reliability in predicting drug toxicity. In addition, we explored the relationship between drug features and toxicity through an interpretive analysis approach, which improved the interpretability of the approach. Our results highlight the potential of Graph Transformers and multi-level fingerprints for accelerating the drug discovery process by reliably, effectively alarming drug safety. We believe that our study will provide vital support and reference for further development in the field of drug development and toxicity assessment.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.compbiomed.2023.106904 | DOI Listing |
Eur J Case Rep Intern Med
August 2025
Department of Internal Medicine, Wayne State University School of Medicine, Trinity Health Oakland Hospital, Pontiac, USA.
Background: Invasive central nervous system (CNS) aspergillosis is rare among human immunodeficiency virus (HIV)-positive patients due to preserved neutrophil function, despite significant CD4+ T-cell depletion. Diagnosis typically requires histopathologic confirmation, but polymerase chain reaction (PCR) testing has introduced new challenges due to its high sensitivity but limited specificity.
Case Presentation: We describe a newly diagnosed 43-year-old HIV-positive male with concurrent Hodgkin lymphoma who presented with progressive neurological decline and a ring-enhancing brain lesion.
Front Immunol
September 2025
Department of Hematology, Cancer Center, the First Hospital of Jilin University, Changchun, China.
Severe aplastic anemia (SAA) is a life-threatening bone marrow failure syndrome that is caused primarily by immune-mediated destruction of hematopoietic stem cells. Traditional treatment relies on immunosuppressive therapy (IST) with antithymocyte globulin (ATG) and cyclosporine (CSA). However, the toxicity and limited availability of ATG have spurred interest in ATG-free regimens.
View Article and Find Full Text PDFMed Int (Lond)
August 2025
Department of Epidemiology, School of Public Health, Zhengzhou University, Zhengzhou, Henan 450001, P.R. China.
Punicalagin, a polyphenolic compound extracted from pomegranate peel, has received increasing attention in recent years due to its antibacterial and antiviral properties. Punicalagin is capable of inhibiting bacterial growth at sub-inhibitory concentrations by affecting cell membrane formation, disrupting membrane integrity, altering cell permeability, affecting efflux pumps, interfering with quorum sensing and influencing virulence factors. Additionally, punicalagin inhibits viruses by modulating enzyme activity, interacting with viral surface proteins, affecting gene expression, blocking viral attachment, disrupting virus receptor interaction and inhibiting viral replication.
View Article and Find Full Text PDFInt J Nanomedicine
September 2025
Department of Infectious Diseases, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, People's Republic of China.
The STING pathway has emerged as a therapeutic target in tumor immunotherapy due to its ability to induce interferon responses, enhance antigen presentation and activate T cells. Despite its therapeutic potential, STING pathway-based tumor immunotherapy has been limited by challenges in poor cellular delivery, rapid degradation of STING agonists, and potential systemic toxicity. Recently, advancements in nanotechnology have tried to overcome these limitations by providing platforms for more accurate and efficient targeted delivery of agonists, more moderate sustained STING pathway activation, and more efficient immune presentation and anti-tumor immune response.
View Article and Find Full Text PDFMater Today Bio
October 2025
School of Pharmacy, Henan Medical University, Xinxiang, Henan, China.
Breast cancer continues to present a major clinical hurdle, largely attributable to its aggressive metastatic behavior and the suboptimal efficacy of standard chemotherapeutic regimens. Cisplatin (CDDP) is a representative platinum drug in the treatment of breast cancer, however, its therapeutic application is often constrained by systemic toxicity and the frequent onset of chemoresistance. Here, we introduce a novel charge-adaptive nanoprodrug system, referred to as PP@, engineered to respond to tumor-specific conditions.
View Article and Find Full Text PDF